Showing 5901-5910 of 8080 results for "".
- Bimekizumab Results Continue to Impress for PsO, HShttps://practicaldermatology.com/news/Bimekizumab-Results-Continue-Impress-PsO-HS/2473847/Dual inhibition with bimekizumab (BIMZELX, UCB) in adults with moderate-to-severe plaque psoriasis demonstrated high efficacy and sustained clinical benefits, according to new long-term data from phase 3 trials and their open-label extensions. Among patients with psoriasis only at baseline
- Rituximab Efficacious for Epidermolysis Bullosa Acquisita: Analysishttps://practicaldermatology.com/news/rituximab-shows-promise-for-epidermolysis-bullosa-acquisita/2473835/Data from a new systematic review indicate rituximab (RTX) may potentially be an effective treatment option for epidermolysis bullosa acquisita (EBA). Due to its chronic nature, management of EBA remains challenging, with remission and flare-up
- Analysis: 3D Imaging Yields Higher Costs Without Detection Benefit in High-Risk Melanoma Patientshttps://practicaldermatology.com/news/analysis-3d-imaging-and-telederm-higher-costs-without-significant-detection-benefit-in-high-risk-melanoma-patients/2471858/New research indicates 3D total-body photography (TBP) paired with sequential digital dermoscopy imaging (SDDI) leads to higher care costs without significantly improving the detection of malignant melanomas when compared to usual care for high-risk patients. <
- riSCC App Launched for Risk Stratification of cSCChttps://practicaldermatology.com/news/riSCC-App-Launched-Risk-Stratification-cSCC/2471817/The not-for-profit organization Skin Cancer Consortium Outcomes (SCOUT) announced it has launched riSCC, a data-driven clinician mobile app designed for risk stratification of cutaneous squamous cell carcinoma (cSCC) in clinical settings. SCOUT, founded in 2018, is committed to transformi
- Biologics Linked to Lower Infection Risk in Older Psoriatic Patients: Studyhttps://practicaldermatology.com/news/biologics-linked-to-lower-infection-risk-in-older-psoriatic-patients-study/2471809/Biologics targeting interleukin (IL)-12, IL-23, and IL-17 were associated with lower rates of serious infection in older adults with psoriatic disease, according to a cohort study using Ontario health data. The study, publishe
- Andrew Weinstein Voted AAD President-Electhttps://practicaldermatology.com/news/Andrew-Weinstein-Voted-AAD-President-Elect/2471798/Andrew H. Weinstein, MD, MPH, FAAD, was voted president-elect of the American Academy of Dermatology (AAD), the organization announced. Dr. Weinstein will be joined by vice president-elect Thomas E. Rohrer, MD, FAAD. Newly elected members of the board of directors are Alina G. Bridges, DO,
- Lipid Metabolites Linked to Atopic Dermatitis Riskhttps://practicaldermatology.com/news/lipid-metabolites-linked-to-atopic-dermatitis-risk/2471714/A two-sample Mendelian randomization (TSMR) study has identified 13 lipid-related metabolite traits that influence the risk of developing atopic dermatitis (AD). Researchers examined genome-wide association study (GWAS) datase
- Secukinumab Reduces Erosions in Psoriatic Arthritis Patientshttps://practicaldermatology.com/news/secukinumab-reduces-erosions-in-psoriatic-arthritis-patients/2471713/Secukinumab significantly reduced erosion progression in patients with psoriatic arthritis (PsA), according to findings from a phase 4 randomized, double-blind, placebo-controlled trial. The study evaluated the impact of the I
- Study: Brepocitinib Reduces Inflammatory Markers in Cicatricial Alopeciahttps://practicaldermatology.com/news/study-brepocitinib-reduces-inflammatory-markers-in-cicatricial-alopecia/2471712/A recent phase 2a clinical trial showed brepocitinib was associated with a significant reduction in C-C motif chemokine ligand 5 (CCL5) expression and improved clinical severity scores in patients with cicatricial alopecia (CA).
- Adverse Event Reporting in Dermatology RCTs Falls Short of CONSORT Harms Guidelines: Analysishttps://practicaldermatology.com/news/adverse-event-reporting-in-dermatology-rcts-falls-short-of-consort-harms-guidelines-analysis/2471683/A new review assessing adverse event (AE) reporting in dermatology randomized controlled trials (RCTs) has significant gaps in adherence to the Consolidated Standards of Reporting Trials (CONSORT) Harms guidelines. The systemat